Catalent acquires Japanese facility to provide local and global clinical supply solutions

Purchase will establish a new clinical GMP manufacturing and distribution hub to support clinical studies

Catalent, a global leader in clinical supply services, has announced a deal to acquire a clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan, from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan.

Financial details of the deal, which is expected to close on 1 July 2020, have not been disclosed.

The 60,000 square foot facility will be the largest in the company’s Asia-Pacific clinical supply network.

The new facility will offer customers access to Catalent’s FastChain demand-led supply services, primary and secondary packaging capabilities, a range of temperature options for storage and distribution, as well as clinical returns and destruction services.

It will operate in partnership with Catalent’s existing Japanese clinical supply facility at Kakegawa, serving both local customers as well as global biotech and pharmaceutical companies.

“This new facility provides much-needed capacity as we look to expand our capabilities across the Asia-Pacific region, and follows on from recent expansions and investments we have made in our clinical supply business in China and Singapore,” commented Ricci Whitlow, President, Catalent Clinical Supply Services.

“Our strategy has been to build expertise and capacity in this region as demand for local clinical supply services increases, to provide support to customers with global programmes and to meet the growing demand in biologics and cell and gene therapy studies.”

Companies